Influenza Reagent
Influenza Virus Infectious
A/Victoria/2570/2019 (H1N1) NYMC X-379
NIBSC code: 22/174
Instructions for use
(Version 2.0, Dated 22/04/2024)

§

# 1. INTENDED USE

Reagent 22/174 was prepared from NYMC X-379 (H1N1), a reassortant of A/Victoria/2570/2019 (H1N1) and X-157 (H3N2), which was processed in 250 $\mu$ l volumes as liquid stock. The derivation and passage history of 22/174 are attached.

# 2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin.

As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

#### 3. UNITAGE

No unitage is assigned to this material.

# 4. CONTENTS

Country of origin of biological material: United Kingdom. Each ampoule contains 250µl (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated hen's eggs.

# 5. STORAGE

Store in the dark at -70°C or below.

Material type: Liquid – will be shipped according to the storage and shipping conditions of the product

# 6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

# 7. USE OF MATERIAL

Ready to use.

# 8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

# 9. REFERENCES

NA



# 10. ACKNOWLEDGEMENTS

NA

#### 11. FURTHER INFORMATION

Further information can be obtained as follows;

This material: enquiries@nibsc.org

WHO Biological Standards:

http://www.who.int/biologicals/en/

JCTLM Higher order reference materials:

http://www.bipm.org/en/committees/jc/jctlm/

**Derivation of International Units:** 

http://www.nibsc.org/standardisation/international\_standards.aspx

Ordering standards from NIBSC:

http://www.nibsc.org/products/ordering.aspx

NIBSC Terms & Conditions:

http://www.nibsc.org/terms\_and\_conditions.aspx

# 12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

#### 13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

# 14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008; Not applicable or not classified

(EC) NO 12/2/20	(EC) No 1272/2008: Not applicable of not classified						
Physical and Chemical properties							
Physical appearance:			Corrosive:	No			
Clear liquid							
Stable:	Yes		Oxidising:	No			
Hygroscopi	No		Irritant:	No			
c:							
Flammable:	No		Handling: See caution, Section 2				
Other	Other Live influenza virus						
(specify):							
Toxicological properties							
Effects of inhalation: Like		lihood of influenza virus infection.					
Effects of ingestion: N		Not	ot established, avoid ingestion				
Effects of	skin	Not	established,	avoid contact with			
absorption:	absorption: skin						
Suggested First Aid							
Inhalation:	Inhalation: Seek medical advice						
Ingestion: Seek medical advice							
Contact with	Wash	with copious amounts of water. Seek					
eyes: medical advice							
Contact with Wash thoroughly with water.							
skin:							

# NIBSC Confidence in Biological Medicines

# Action on Spillage and Method of Disposal

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water

Absorbent materials used to treat spillage should be treated as biological waste.

# 15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About\_Us/Terms\_and\_Conditions.aspx or

upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

# 16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes\*: United Kingdom \* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.

Net weight: 0.25g per vial.

Toxicity Statement: Non-toxic

Veterinary certificate or other statement if applicable.

Attached: No

# Passage history of NYMC X-379 (H1N1)

Cumulative number of passages	Passage numbers at each stage	Lot	Laboratory
E6	E4/E2	# 3000827519	CDC, USA
E7	E4/E2/E1	unknown	NYMC, USA
E15	E4/E2/E1/E8	#6521	NYMC, USA
E16	E4/E2/E1/E8/E1	47150*	NIBSC, UK

\*The HA titre of this virus in 0.7% Turkey red blood cells is 256. The infectious titre is unknown.

Sterility: No visible contamination was detected in a variety of media (tryptone soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates) after 14 days incubation.

The HA and NA sequences of this virus are available at GISAID with the accession number EPI\_ISL\_ 15157783.



# Derivation of NYMC X-379 A/Victoria/2570/2019 (H1N1pdm) with NYMC X-157 CL-3 High Yield A H1N1pdm Reassortant (6:2) with A/PR/8/34 M, PB1, PB2, PA, NS and NP genes and A/Victoria/2570/2019 HA and NA genes

Exper. # 4884


A/Victoria/2570/2019, H1N1pdm

CDC # 3000827519


E4/E2 (11/22/19 (date of collection), 8/31/20(date of pool))

HA: 64

# Passages at New York Medical College







HA Yield by UPLC Analysis (µg HA/ml allantoic fluid)

wt (wild type)	X-379	Fold Increase
4.4	7.5	1.7

HA and NA, genes were identified as A/Victoria/2570/2019 by RT-PCR/RFLP gene analysis. The M, PB1, PB2, PA, NS and NP genes were identified as A/PR/8/34 by RT-PCR/RFLP analysis.

SPF eggs were used for all reassortant passages.

Virus seed was shown to be sterile. Sterility testing was performed by streaking the sample on blood agar plates and incubating for 48 hours at 37 °C.

All titres performed with chicken red blood cells.